

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

## **VOLUNTARY ANNOUNCEMENT- FIRST SUBJECT DOSED WITH JS016 INJECTION**

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.\* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the first subject has been dosed in the Phase I clinical study of JS016 injection (project code: JS016), which has been approved by the National Medical Products Administration recently. The study is designed as a randomized, double-blind and placebo-controlled study, aiming at evaluating the tolerability, safety and pharmacokinetic and immunogenicity of JS016 among the Chinese population, which provide a basis for the subsequent clinical studies of JS016.

### **ABOUT JS016 INJECTION**

JS016 is a recombinant fully human monoclonal neutralizing antibody that is specific to the SARS-CoV-2 surface spike protein receptor binding domain and can effectively block the binding of viruses to host cell surface receptor ACE2. The product is jointly developed by the Company and the Institute of Microbiology, Chinese Academy of Sciences (the “**IMCAS**”) (for further details, please refer to the announcement of the Company dated 20 March 2020).

At the beginning of the COVID-19 outbreak, the Company rapidly launched the research and development program of neutralizing antibodies to combat COVID-19. Within two months, the Company has completed IND enabling pre-clinical studies, the process development and production for GLP toxicity study and GMP production of clinical material by leveraging the Company’s platform technology. JS016 is the first SARS-CoV-2 neutralizing antibody that has entered the clinical stage in China, with a leading position in terms of leading development speed across the globe.

The Company will disclose product development information in a timely manner based on the clinical progress of the pipeline product under the disclosure obligation.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company may not be able to ultimately develop and market JS016 successfully. Investors are reminded to exercise caution.

By order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

Shanghai, the PRC, 7 June 2020

*As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive Directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. He Jia, Mr. Chen Xinjun, Mr. Qian Zhi and Dr. Roy Steven Herbst as independent non-executive Directors.*

\* For identification purpose only